A new drug undergoing human clinical trials for eliminating fat cells
RESEARCH CHEMICAL ONLY AT THIS STAGE.
- Established: 2011
- Founder: Dr. Wadih Arap and Renata Pasqualini
- Accessibility: Not yet available
- Diet Type: Diet and cancer pill
- Gender: Male and female
Adipotide is a new drug that is showing some promise in the area of obesity research. This drug was initially created as a cancer treatment designed to starve cancer cells of a blood supply so they would stop growing. The effects of Adipotide have shown that the drug actually starves fat cells of blood forcing them to die and be reabsorbed into the body. Initial tests were done on rats and then moved on to monkeys. The results from testing on rats showed a 30 percent decrease in body weight. After four weeks of daily injections of Adipotide followed by four weeks of non-treatment, 10 obese female rhesus monkeys lost an average of 11 percent of their body weight and 39 percent of fat deposits. Most of the loss was experienced during the non-treatment period.
The news isn’t all great where this drug is concerned though. Some of the main negative side effects to this drug included dehydration and small kidney lesions, which left untreated could lead to kidney failure. Once the drug was discontinued, these problems disappeared. However, as the drug progresses to human clinical trials, these side effects will need to be dealt with. Adipotide is still a long way from being available for purchase, but the initial studies do make it sound promising.
- Initial studies look promising
- Drug has been proven to reduce body weight and fat deposits in rats and monkeys
- Fat loss continues even after drug is discontinued
- Completely starves fat cells of blood supply so they die
- Drug causes dehydration
- Can produce kidney lesions
- Still in the initial testing phases
- Raises more questions than answers at this point
The initial studies on Adipotide sound very promising, but there are some definite concerns that need to be addressed before this drug is available for human consumption. The drug was found to be ineffective for monkeys who were already lean so it also raises the question of if this drug would stop working once a certain weight or body fat level is reached. It appears that Adipotide is going through the proper channels for testing. This could be a great breakthrough in obesity research, but we must all remember the importance of addressing potentially dangerous side effects.
What is Adipotide
FTPP (Adipotide) is a peptidomimetic (a small protein-like chain designed to mimic a peptide), transformed into an experimental proapoptotic drug used for cellular death. Its purpose is to contribute to the weight loss. This substance has shown favorable results in tests and its main feature is its property of rapid loss weight.
How does it work?
Adipotide is designed to target specific blood vessels, supplying adipose tissue with blood. This process causes a shrinking effect on vessels, which forces the fat cells to feed on those vessels. All this mechanism gives origin to an apoptosis, which is a process of programmed cell death of multicellular organisms. There are two receptors where Adipotide binds: ANXA2 and prohibitin; these are found in blood vessels and accomplish the function of supplying white adipose tissue.
Results and benefits
Due to the laidback lifestyle of people and the contemporary work modality, the need of practicing physical activity has decreased, this causes more people to become overweight and obese. Adipotide help people in reducing their weight in a few months. When Adipotide cuts off the blood supply to fat cells, this process causes the loss of a certain amount of body weight and at the same time an additional amount of belly fat mass loss.
It contains potentiating effects on insulin sensitivity, improving it drastically. It is reflected in a more efficient use of insulin on the body, which has a positive effect on reducing elevated blood glucose levels. This process maintains health and allows the use of the energy from the chemical nutrients that the body receives.
Some studies have shown that Adipotide causes metabolic syndrome symptoms that increase thirst and urination, develop fatigue (tiredness) and cause blurred vision. Those are effects related to this peptide and it is advisable to be aware of them.
However, studies have not shown transcendent adverse effects. Participants in the case study showed no symptoms of nausea or appetite loss.
But this drug can generate adverse effects on kidney; these effects are dose-dependent and those are reversible injuries. Some of these effects are shown as reactive/regenerative and reactive/regenerative lesions in this organ. The kidney plays three key roles in the human body: it regulates water (removing the water excess but retaining it at the right time), balances the body’s minerals (allowing the correct functionality of the body), and processes hormones (useful on the regulation of blood pressure). In these facts lays the importance of the kidney, as well as the possible effects that could affect its proper operation.